» Articles » PMID: 35888690

Uptake of COVID-19 Booster Dose Among Saudi Arabian Population

Overview
Publisher MDPI
Specialty General Medicine
Date 2022 Jul 27
PMID 35888690
Authors
Affiliations
Soon will be listed here.
Abstract

: Although several vaccines have been produced and administered around the world, new SARS-CoV-2 worsened the COVID-19 infection risk and impacted the initial vaccine dosage effectiveness. Based on studies indicating that the third and fourth COVID-19 vaccine doses significantly reduced COVID-19 transmission, Saudi Arabia has been administering COVID-19 booster vaccine doses to its citizens. The purpose of this study was to evaluate the uptake of the COVID-19 vaccine booster in relation to the socio-demographic characteristics and other associated factors among the Saudi population. : This study was an online analytical cross-sectional study using a self-administered questionnaire. Pearson Chi-square test and multiple logistic regression analyses were used to determine factors associated with the uptake of COVID-19 booster dose vaccines. : A total of 2332 responded to our study. Overall, 527 (22.6%) participants had received a booster dose. An age of 55 and above (aOR: 5.415; 95% CI: 2.719-10.783), Eastern region (aOR: 2.513; 95% CI: 1.566-4.033), history of influenza vaccination at annual intervals (aOR: 2.387; 95% CI: 1.730-3.293), the first dose of Moderna vaccine (aOR: 1.324; 95% CI: 1.160-1.510), and cancer (aOR: 2.161; 95% CI: 1.218-3.879) were independent factors most associated with a higher uptake of the COVID-19 vaccine booster dose. In contrast, the second dose of Moderna vaccine (aOR: 0.794; 95% CI: 0.683-0.922), AstraZeneca vaccine (aOR: 0.691; 95% CI: 0.509-0.939), strong symptoms from side effects after the second dose of the COVID-19 vaccine (aOR: 0.615; 95% CI: 0.404-0.935) were independent factors most associated with a lower uptake of the COVID-19 vaccine booster dose. : Our findings indicate low COVID-19 vaccine booster uptake. This necessitates the need for strategies to address discouraging factors of the COVID-19 vaccine booster dose uptake and engage the Saudi population to raise awareness about the importance of the booster dose.

Citing Articles

Exploring the relationship between experience of vaccine adverse events and vaccine hesitancy: A scoping review.

Gauna F, Raude J, Khouri C, Cracowski J, Ward J Hum Vaccin Immunother. 2025; 21(1):2471225.

PMID: 40058398 PMC: 11901385. DOI: 10.1080/21645515.2025.2471225.


Post-Pandemic Perspectives: Willingness, Risk Perception and Factors Influencing COVID-19 Booster Vaccine Uptake Among Thai Healthcare Workers and Vulnerable Populations.

Kitro A, Sirikul W, Polpitakchai C, Panumasvivat J, Yamsiri R, Tasena P Vaccines (Basel). 2025; 12(12.

PMID: 39772043 PMC: 11680416. DOI: 10.3390/vaccines12121381.


Impact of the COVID-19 vaccination on confusion around vaccination in general: A longitudinal study on a university population over 18 months.

Paridans M, Monseur J, Gillain N, Husson E, Darcis G, Saegerman C PLOS Glob Public Health. 2024; 4(12):e0004066.

PMID: 39700212 PMC: 11658518. DOI: 10.1371/journal.pgph.0004066.


Community pharmacists' knowledge, beliefs, and perceived barriers toward vaccination services at community pharmacies: A cross-sectional study from Saudi Arabia.

Alrasheedy A, Alharbi A, Alturaifi H, Alkhamis R, Almazyad R, Almozaini S Hum Vaccin Immunother. 2024; 20(1):2414551.

PMID: 39693183 PMC: 11487963. DOI: 10.1080/21645515.2024.2414551.


Global disparities in COVID-19 vaccine booster dose (VBD) acceptance and hesitancy: An updated narrative review.

Nath Roy D, Ferdiousi N, Hossen M, Islam E, Azam M Vaccine X. 2024; 18:100480.

PMID: 38585380 PMC: 10997838. DOI: 10.1016/j.jvacx.2024.100480.


References
1.
Lai X, Zhu H, Wang J, Huang Y, Jing R, Lyu Y . Public Perceptions and Acceptance of COVID-19 Booster Vaccination in China: A Cross-Sectional Study. Vaccines (Basel). 2021; 9(12). PMC: 8709447. DOI: 10.3390/vaccines9121461. View

2.
Dror A, Eisenbach N, Taiber S, Morozov N, Mizrachi M, Zigron A . Vaccine hesitancy: the next challenge in the fight against COVID-19. Eur J Epidemiol. 2020; 35(8):775-779. PMC: 8851308. DOI: 10.1007/s10654-020-00671-y. View

3.
Kuhlmann C, Mayer C, Claassen M, Maponga T, Burgers W, Keeton R . Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet. 2022; 399(10325):625-626. PMC: 8765759. DOI: 10.1016/S0140-6736(22)00090-3. View

4.
Antonelli M, Penfold R, Merino J, Sudre C, Molteni E, Berry S . Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2021; 22(1):43-55. PMC: 8409907. DOI: 10.1016/S1473-3099(21)00460-6. View

5.
Al-Hanawi M, Ahmad K, Haque R, Keramat S . Willingness to receive COVID-19 vaccination among adults with chronic diseases in the Kingdom of Saudi Arabia. J Infect Public Health. 2021; 14(10):1489-1496. DOI: 10.1016/j.jiph.2021.08.002. View